Cargando…

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

PURPOSE: The EORTC-26101 study was a randomized phase II and III clinical trial of bevacizumab in combination with lomustine versus lomustine alone in progressive glioblastoma. Other than for progression-free survival (PFS), there was no benefit from addition of bevacizumab for overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kessler, Tobias, Schrimpf, Daniel, Doerner, Laura, Hai, Ling, Kaulen, Leon D., Ito, Jakob, van den Bent, Martin, Taphoorn, Martin, Brandes, Alba A., Idbaih, Ahmed, Dômont, Julien, Clement, Paul M., Campone, Mario, Bendszus, Martin, von Deimling, Andreas, Sahm, Felix, Platten, Michael, Wick, Wolfgang, Wick, Antje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543963/ https://www.ncbi.nlm.nih.gov/pubmed/37494539 http://dx.doi.org/10.1158/1078-0432.CCR-23-0926

Ejemplares similares

Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
por: Caramanna, Ivan, et al.
Publicado: (2022)

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes
por: Kessler, Tobias, et al.
Publicado: (2020)

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma
por: Kaulen, Leon D, et al.
Publicado: (2022)

Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
por: Seidel, Clemens, et al.
Publicado: (2011)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2015)

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
por: Kickingereder, Philipp, et al.
Publicado: (2015)

Neurocognitive impairment and patient–proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients
por: Caramanna, Ivan, et al.
Publicado: (2022)

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)
por: Baumert, Brigitta G., et al.
Publicado: (2016)

Conventional and emerging treatments of astrocytomas and oligodendrogliomas
por: Kessler, Tobias, et al.
Publicado: (2022)

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
por: Grassl, Niklas, et al.
Publicado: (2023)

Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
por: Blobner, Jens, et al.
Publicado: (2021)

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
por: Wick, A., et al.
Publicado: (2022)

PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS
por: Stichel, Damian, et al.
Publicado: (2020)

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2020)

Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2022)

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease
por: Breckwoldt, Michael O., et al.
Publicado: (2019)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2): A follow‐up study
por: Doubrovinskaia, Sofia, et al.
Publicado: (2022)

Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
por: Ott, Martina, et al.
Publicado: (2012)

K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
por: Bunse, Lukas, et al.
Publicado: (2022)

Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23
por: Hau, Peter, et al.
Publicado: (2021)

Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series
por: Kaulen, Leon D., et al.
Publicado: (2021)

Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients
por: Dirven, Linda, et al.
Publicado: (2021)

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
por: Lassman, Andrew B., et al.
Publicado: (2022)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients—An Analysis Within the EORTC 22033 Clinical Trial
por: Jaspers, Jaap, et al.
Publicado: (2019)

The aryl hydrocarbon receptor in tumor immunity
por: Platten, Michael, et al.
Publicado: (2012)

Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)

Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
por: Idbaih, Ahmed, et al.
Publicado: (2010)

PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS
por: Sill, Martin, et al.
Publicado: (2020)

Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042–26042
por: Maas, Sybren L. N., et al.
Publicado: (2023)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria
por: Lanese, Andrea, et al.
Publicado: (2018)

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033
por: Klein, Martin, et al.
Publicado: (2020)

Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients
por: Dirven, Linda, et al.
Publicado: (2017)

Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma
por: Leone, Riccardo, et al.
Publicado: (2023)

Automated brain extraction of multisequence MRI using artificial neural networks
por: Isensee, Fabian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p440mi8oaitbctubvb9f3j955b